Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-23
2007-10-23
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S093100, C424S093210, C424S184100, C514S04400A
Reexamination Certificate
active
10420278
ABSTRACT:
The invention provides a method of radiosensitizing a tumor in a subject by contacting the tumor with a cytokine or a nucleic acid molecule encoding a cytokine. The invention also provides a method of radiosensitizing a tumor in a subject by administering, at a site other than the tumor, a cell genetically modified to express a cytokine. The invention further provides a method of reducing the severity of a cancer in a subject by administering a cytokine at the site of the tumor or by immunizing the subject at a site other than the tumor with tumor cells genetically modified to express a cytokine, and treating the tumor with radiotherapy.
REFERENCES:
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5674486 (1997-10-01), Sobol et al.
patent: 5925362 (1999-07-01), Spitler et al.
patent: 6423311 (2002-07-01), Mardiney et al.
Garland et al, Br J Cancer. Aug. 1983;48:247-59.
McBride et al, Folia Biologica 1994;40:62-73.
Bodey et al, Anticancer Res 2000;20:2665-76.
Radoja et al, Mol Med 2000;6:465-79.
Ganser et al, Am J Clin Oncol 1991;14:S51-S63.
Cao et al, Stem Cells 1998;16 suppl:251-60.
Brown, “Gene Therapy “Oversold” by Researchers, Journalists—NIH Advisers Cite Nearly Uniform Failure”The Washington PostA22 (1995).
Chattergoon et al., “Genetic immunization: a new era in vaccines and immune therapeutics,”The FASEB Journalvol. 11, pp. 753-763 (Aug. 1997).
Chiang et al., “Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo,”Cancer Res.57(18): 3899-3903 (1997).
Coghlan, “Gene dream fades away,”New Sci148:14-15 (Nov. 25, 1995).
Colombo, et al., “Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo,”J. Exp. Med.173, pp. 889-897(Apr. 1991), The Rockefeller University Press 0022-1007/91/04/0889/09.
Dang et al., “Gene therapy and translational cancer research,”Clin. Cancer Res.5(2): 471-474 (1998).
Deonarain, “Ligand-targeted receptor-mediated vectors for gene delivery,”Exp. Opin. Ther. Patents8(1): 53-69 (1998); Ashley Publications Ltd. ISSN 1354-3776.
Dranoff et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity,”Proc. Nat. Acad. Sci. USA., vol. 90, pp. 3539-3543 (Apr. 1993).
Finn, “Tumor-rejection antigens recognized by T lymphocytes,”Curr Opin Immunol.5(5):701-708 (1993); Current Biology Ltd ISSN 0952-7915.
Gansbacher et al., “Retroviral vector-mediated cytokine-gene transfer into tumor cells,”Cancer Invest.11(3):345-354 (1993), Marcel Dekker, Inc.
Golumbek et al., “Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.”Cancer Res.53(2):5841-5844 (Dec. 15, 1993).
Horton et al., A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α,Proc Natl Acad Sci USAvol. 96, pp. 1553-1558 (Feb. 1999), www.pnas.org.
Lange et al., “A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.”,J Immunother.12(4):265-271 (1992), Raven Press, Ltd., New York.
Marshall, “Gene therapy's growing pains,”Science269(5227):1050-1055 (Aug. 25, 1995).
Matsumoto et al., “Recombinant human granulocyte colony-stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice.”Int J Cancer49(3):444-449 (1991), Wiley-Liss, Inc.
McBride et al., “Modification of tumor microenvironment by cytokine gene transfer,”Acta Oncologica, vol. 34, No. 3, pp. 447-451 (1995); Scandinavian University Press, ISSN 0284-186X.
McBride et al., “Interleukin-3 in gene therapy of cancer,”Folia Biologica(Praha) 40(1-2):62-73 (1994).
McBride and Dougherty, “Radiotherapy for genes that cause cancer.”Nature Medicine, vol. 1, No. 11, pp. 1215-1217 (Nov. 1995).
McCluskie et al., “Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates,”Mol. Med.5(5):287-300 (1999).
McDonald et al., “Combined betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer.”Int J Radiat Oncol Biol Phys.27(3):613-619 (1993), Pergamon Press Ltd. 0360-3016/93.
Miller and Vile, “Targeted vectors for gene therapy,”FASEB J.9(2):190-199 (Feb. 1995); FASEB, 0892-6638/95/0009-0190.
Mitchell, “Combining chemotherapy and biomodulation in the treatment of cancer,”UCLA Symposium at Keystone, Colorado 99:345-358 Metzgar and Mitchell ed., (1989), Alan R. Liss, Inc., New York, ISBN 0-8451-2698-9.
Oshikawa et al., “Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer,”Human Gene Ther.vol. 12, pp. 149-160 (Jan. 20, 2001); Mary Ann Liebert, Inc.
Palmer et al., “Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes,”Proc. Natl. Acad. Sci USA, vol. 88, pp. 1330-1334 (Feb. 1991), Cell Biology.
Patchen et al., “Mast cell growth factor (C-KitLigand) in combination with granulocyte macrophage colony-stimulating factor and interleukin-3: in vivo hemopoietic effects in irradiated mice compared to in vitro effects,”Biotherapy7(1):13-26 (1994); Kluwer Academic Publishers.
Riddell et al., “T-Cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients,”Nat Med.2(2):216-223 (Feb. 1996).
Rochlitz et al., “Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors,”Cancer Gene Ther.6(3):271-281 (1999); Stockton Press 0929-1903/99.
Sersa et al., “Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy,”Int. J. Cancer42(1):129-134 (1988); Alan R. Liss, Inc.
Tepper and Mule, “Experimental and clinical studies of cytokine gene-modified tumor cells,”Human Gene Ther.5(2):153-164 (1994); Mary Ann Liebert, Inc.
Thomas et al., “Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine,”Human Gene Ther.9(6):835-843 (Apr. 10, 1998); Mary Ann Liebert, Inc.
Verma and Somia, “Gene therapy-promises, problems and prospects,”Nature389(6648): 239-242 (Sep. 18, 1997).
Vieweg and Gilboa, “Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment,”Cancer Invest.13(2):193-201 (1995); Marcel Dekker, Inc.
Vieweg et al., “Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines,”Cancer Res.54(7):1760-1765 (Apr. 1, 1994).
Weichselbaum, et al., “Gene therapy targeted by radiation preferentially radiosensitizes tumor cells,”Cancer Res.54(6):4266-4269 (Aug. 15, 1994).
Younes et al., “Radiation-induced effects on murine kidney tumor cells: role in the interaction of local irradiation and immunotherapy.”J Urol.153(6):2029-2033 (Jun. 1995); American Urological Association, Inc., 0022-5347/95/1536-2029.
Zhang and Fang., “Gene therapy strategies for cancer,”Expert Opin Investig Drugs4(6):487-514 (Jun. 1995); Ashley Publications Ltd., ISSN 1354-3784.
Li Q. Janice
The Regents of the University of California
LandOfFree
Tumor radiosensitization using gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor radiosensitization using gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor radiosensitization using gene therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3824885